
The C.D.C. Now Says Healthy Kids Don't Need Covid Shots. Is That True?
The Centers for Disease Control and Prevention will no longer advise that healthy children receive routine Covid shots, a significant departure from its previous approach of suggesting annual shots for everyone age 6 months and older.
Health Secretary Robert F. Kennedy Jr. announced the change on X on Tuesday, citing a lack of data to support shots for healthy children. The move echoes Mr. Kennedy's longstanding skepticism about the need to vaccinate children against the virus, and comes less than a week after the Food and Drug Administration said it may require additional testing before allowing Covid shots to be used for younger, healthy Americans. Mr. Kennedy, who as health secretary oversees both the C.D.C. and the F.D.A., has repeatedly said that children are at almost no risk from Covid.
It's true that for many children, a case of Covid will be inconsequential. They might have a runny nose, a cough or other mild symptoms, if any at all, and bounce back within a few days. But some children do become seriously ill and, in rare cases, die from their infections. And data shows that over one million U.S. children have developed long Covid.
That discrepancy is at the root of a continuing debate among medical researchers about just how much of a risk Covid poses to children, and whether they should receive annual vaccines against it.
Many agree that the original course of vaccination offered significant protection against serious illness in children. Data from the Centers for Disease Control and Prevention shows that two or more doses of Covid vaccines were 40 percent effective at preventing emergency room visits and hospitalizations among children under the age of 5. The agency has for years recommended Covid vaccines for everyone 6 months or older, and the American Academy of Pediatrics also recommends vaccinating children and adolescents.
But the question of whether children need annual vaccines to protect against the latest circulating variants is more contentious. Children might not benefit as much as adults would from a yearly shot because their immune systems can remember vaccinations for much longer, said Dr. Michael Mina, a former professor of epidemiology at the Harvard T.H. Chan School of Public Health who has extensively studied Covid. Another argument against annual shots is that most children in the United States now have some degree of protection from previous infections or vaccinations.
Those in favor of annual vaccines for children stress that protection from vaccines or infections wanes over time, especially as new variants emerge, and so they can benefit from another dose. And emerging evidence shows that vaccination may protect against long Covid — although that is far from settled science.
'We know that Covid's still out there — we can prevent it, and the vaccine has got no appreciable side effects,' said Dr. Chris Forrest, a professor of pediatrics at Children's Hospital of Philadelphia. 'So I think it's a totally positive value proposition.'
This added protection may be especially important for children with underlying conditions, and for those who live with relatives who are older or at high risk of severe illness.
'The more comorbid illnesses the child has, the quicker I would be in general to consider Covid vaccination,' said Dr. Aaron Glatt, the chair of the department of medicine at Mount Sinai South Nassau in Oceanside, N.Y. 'And the reverse would be true. A perfectly healthy 3-year old, he doesn't have any medical problems, he's had Covid once or twice — I'm not sure that there's any scientific data to support vaccination.'
But, he added, 'it doesn't mean that it would be wrong or dangerous to give it.'
Ultimately, doctors said, the question comes down to how families make sense of the risk to their children. Here's what the data shows.
How mild is Covid usually for children?
It is difficult to get good data on what share of pediatric cases are mild, but doctors say most children develop few symptoms.
Some of the best information on children we have is from 2020, before children had built up widespread immunity from vaccination or infections. A review of studies from that year found that around 4 percent of children with Covid worldwide developed severe symptoms, which can include difficulty breathing, high fever and chest pain.
How likely is it that children will be hospitalized with or die from Covid?
Children who have Covid are generally at a low risk for hospitalization. About 234,000 children in the United States were hospitalized with infections between September 2020 and April 2024. Though the virus has led to milder disease over time, children and teenagers still accounted for about 4 percent of hospitalizations related to Covid between October 2024 and March 2025.
The risk is higher for babies younger than 6 months. From October 2022 to April 2024, young infants were more likely to be hospitalized than any other age group apart from adults 75 and older.
Pediatric Covid deaths are very rare. Provisional data from the C.D.C. shows over 1800 children in the United States have died from Covid. Unicef has said that more than 17,400 children and adolescents under 20 years old around the globe have died from Covid.
Are only children with underlying health conditions falling seriously ill?
In an April appearance on Fox News, Mr. Kennedy said that some children with 'very profound morbidities may have a slight risk' from Covid, but that 'most kids don't.'
But C.D.C. data from July 2023 to March 2024 found that half of children who were hospitalized because of Covid had no underlying medical conditions.
It is true that underlying health conditions like obesity, diabetes, heart disease and chronic lung diseases raise the risk of hospitalization. Children with these and other conditions will still be able to be vaccinated.
But the increase in risk isn't small. Research has shown that young people with at least one underlying condition are 28 percent more likely than those with no underlying conditions to end up in critical care with Covid, and are 125 percent more likely to die from it. The more underlying conditions a child has, the greater the risk.
On a recent episode of 'Dr. Phil Primetime,' Mr. Kennedy claimed that people who died from Covid 'were so sick that they were basically hanging from a cliff, and Covid came along and stamped on their fingers and dropped them off.'
Doctors noted that just because children had underlying conditions did not mean they were in extremely poor health before they were infected.
'That's totally a not correct assessment, that it was only children who otherwise were going to die, and it just took them out,' said Dr. Sarah Long, a professor of pediatrics at Drexel University College of Medicine who has advised the C.D.C. and F.D.A.
And despite Mr. Kennedy's claim during an event last year that there isn't 'a single healthy kid who died from Covid,' even children without pre-existing health issues have become seriously sick or, in rare cases, have died. A review of data on 183 pediatric Covid deaths from 2020 to 2022 found that 32 percent of children who died did not have another medical condition.
Does vaccinating pregnant women protect infants?
Mr. Kennedy also announced on Tuesday that the C.D.C. will no longer recommend healthy pregnant women be vaccinated against Covid. Pregnant women are at a far higher risk of severe disease from Covid.
Vaccinating pregnant women also reduces the risk that their infants will be hospitalized from Covid. Babies under six months are at higher risk of hospitalization from Covid, in part because their immune systems are so fragile, and they are not able to be vaccinated.
What about the risk of myocarditis?
Mr. Kennedy has claimed that Covid vaccines have 'huge associations' with types of heart inflammation, called myocarditis or pericarditis. The shots have been linked to this issue in rare cases, particularly among adolescent boys. Most instances of myocarditis associated with vaccines have been mild. One analysis of nearly four million people who received booster shots found 28 instances of probable or confirmed myocarditis, all of which resolved quickly.
Covid-19 vaccinescarry note the minor risk of heart inflammation to young men on their warning labels. Last month, the F.D.A. told Pfizer and Moderna to broaden that warning to include boys between the ages 16 and 25, citing data that showed about 38 cases of heart inflammation per million doses among this age group.
Research has consistently shown that the virus itself is far more likely to cause this inflammation. One review found that the risk of myocarditis after infection was more than seven times greater than the risk after vaccination.
What's the risk of long Covid?
Estimates of long Covid among children vary widely. But even at the lower end, studies show that around 1 percent of children in the United States, or roughly one million children, have ever had long Covid, broadly defined as symptoms that persist or emerge at least three months after an infection. These include many children who had mild or asymptomatic infections.
The condition commonly causes children to experience fatigue, dizziness, shortness of breath and trouble concentrating and sleeping.
'We see kids that are having huge impacts on their everyday activities — they can no longer go to school because they're having such profound fatigue or other symptoms,' said Dr. Laura Malone, the director of the Pediatric Post-Covid-19 Rehabilitation Clinic at the Kennedy Krieger Institute. 'These kids are not able to play sports or go to their school dances,' she added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Former LeBron James Teammate Tells Wild Club Story About Lakers Star
Former LeBron James Teammate Tells Wild Club Story About Lakers Star originally appeared on Athlon Sports. Los Angeles Lakers star LeBron James takes precise care of his body, which has helped him play 22 seasons in the NBA at an elite level. Advertisement James is 40 years old. He's the oldest active player in the NBA. The average person wouldn't know that by watching him play, as James made the All-NBA Second Team this year and became the oldest player in NBA history to receive an MVP vote, breaking Michael Jordan's 23-year-old record. A four-time MVP, James has played for the Cleveland Cavaliers (twice), Miami Heat and Lakers. He's a four-time champion and a four-time Finals MVP. James is the only player in NBA history to win a Finals MVP Award with three teams. Los Angeles Lakers star LeBron James© Soobum Im-Imagn Images A future Hall of Famer, James won his first two titles with the Heat in 2012 and 2013. Mario Chalmers, who was on those Miami teams, recently told NFL legend Shannon Sharpe that James used to get treatment in the clubs. Advertisement "I tell people this all the time, Bron will really get treatment if he was in the club. Like, he would literally have something on his knees or something on his back inside the club. So it's like why is somebody doing that, like that's a real dedication to just be in the club with treatment." Chalmers said. Sharpe went on asking what were the kind of treatments he is doing in the club. "Not ice bags, it'd be like the stim, like the stim machine that shoot electrolyte or electricity in your knees and stuff like that. He always have something [for] recovery." James has said many times that he takes recovery very seriously. The leading scorer in NBA history has never undergone surgery on his body because of an injury. The small forward is arguably the most durable athlete in NBA history. Advertisement Arguably the greatest player of all time, James has career averages of 27.0 points, 7.5 rebounds, 7.4 assists, 1.5 steals and 0.7 blocks. He's the only player in NBA history to rank top five all-time in points and assists. James, who turns 41 in December, has a player option to return to the Lakers next season worth $52.6 million. The King is widely expected to pick up his option and play his 23rd NBA season. Related: Shai Gilgeous-Alexander Predicted to Repeat Feat Not Seen Since LeBron James This story was originally reported by Athlon Sports on Jun 1, 2025, where it first appeared.


Fox News
35 minutes ago
- Fox News
Massachusetts Governor demands answers after ICE arrests Milford High School student
Massachusetts Gov. Maura Healey took to social media Sunday evening to demand answers after ICE agents arrested a high school student heading to volleyball practice over the weekend. The student, 18-year-old Marcelo Gomes, is a junior at Milford High School in Milford, Massachusetts. In her post, Healey says she is "disturbed and outraged" and that she wants answers immediately explaining why the student was taken into immigration enforcement's custody. "I'm demanding that ICE provide immediate information about why he was arrested, where he is and how his due process is being protected," she s. In the post she blames the Trump admin for what she describes as an attempt to create fear. "The Trump Administration continues to create fear in our communities, and it's making us all less safe," her post states. In her statement, Healey claims that the student was detained on Saturday without any warning or subsequent explanation provided to state officials. "Yet again, local officials and law enforcement have been left in the dark with no heads up and no answers to their questions," she said. The community gathered to protest outside of Milford on Sunday. Hundreds demanded Gomes be set free and that ICE stop harassing members of their community. U.S. Rep. Jake Auchincloss, a Democrat who represents Milford in Congress, attended the protest and made note on X that Gomes was "enrolled in honors classes, a coaching assistant for girls volleyball [and] player for boys volleyball, and a member of the school band." "This administration has its public safety priorities backwards. It pardons cop-beaters from Jan. 6 but detains high-school volleyball players. It makes gun-purchaser background checks harder while pushing for tax breaks to buy silencers for pistols. This reckless behavior does not make the residents of Milford safer, and I stand with the community in support of law [and] order," he wrote. Milford School District Superintendent Kevin McIntyre says that Gomes' detention is one of many apprehensions to take place in the southern Massachusetts community. McIntyre says the district cannot take any role in immigration enforcement, but they will "support all of our students and families, including those who are immigrants to the United States." "They are members of the community, students in our classrooms, athletes that compete representing Milford, musicians, artists, friends, and neighbors. We will do everything in our power to support our students and families during these difficult times," he said in his statement. Sunday morning was Milford High School's graduation and Healey says a day of celebration has now been tarnished. "My heart goes out to the Milford community on what was supposed to be a celebratory graduation day," she said.


Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.